In the coronavirus efficacy (COVE) phase 3 clinical trial, vaccine recipients were assessed
for neutralizing and binding antibodies as correlates of risk for COVID-19 disease and as …

In 1993, Malawi became the first African country to replace chloroquine with sulfadoxine-pyrimethamine
nationwide in response to high rates of chloroquine-resistant falciparum malaria…

Background Whether a broadly neutralizing antibody (bnAb) can be used to prevent human
immunodeficiency virus type 1 (HIV-1) acquisition is unclear. Methods We enrolled at-risk …

Molecular assays for monitoring sulfadoxine-pyrimethamine-resistant Plasmodium falciparum
have not been implemented because of the genetic and statistical complexity of the …

Mounting evidence has revealed pathological interactions between HIV and malaria in dually
infected patients, but the public health implications of the interplay have remained unclear. …

Chemotherapy remains the only practicable tool to control falciparum malaria in sub-Saharan
Africa, where >90% of the world's burden of malaria mortality and morbidity occurs. …

Background The MRKAd5 HIV-1 gag/pol/nef subtype B vaccine was designed to elicit T-cell-mediated
immune responses capable of providing complete or partial protection from HIV-1 …

… Data were analysed by P Patnaik with support by W Miller, I Hoffman, and J Kublin. The
manuscript was prepared by P Patnaik and J Kublin, and all authors contributed to the editing of …

Background A safe, effective vaccine is essential to eradicating human immunodeficiency
virus (HIV) infection. A canarypox–protein HIV vaccine regimen (ALVAC-HIV plus AIDSVAX B/…

Measuring immune correlates of disease acquisition and protection in the context of a clinical
trial is a prerequisite for improved vaccine design. We analysed binding and neutralizing …